CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects Post Contentcrsp, vrtxRead More You might also be interested in reading WaFd misses Q1 estimates. September 18, 2025 In Mainstream ← Previous post Next post →